Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 2,216 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blinded (placebo) Clear all

Conditions: Lyme Disease
Interventions: VLA15, Normal Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 65
States / cities: Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Healthy
Interventions: Hallucinogens and psychoactive substances; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anthrax
Interventions: AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL); Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more

Conditions: Scar Prevention, Scar Reduction
Interventions: AZX100 Drug Product, Placebo; Drug
Lead sponsor: Capstone Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas

Conditions: Alcohol Abuse
Interventions: Protandim; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: General Surgery
Interventions: Sugammadex, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Jacksonville, Florida • Houston, Texas

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Placebo for Ocrelizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 13
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Letrazuril; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York

Conditions: Healthy Volunteer
Interventions: TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: JOB's Syndrome, Hyper-IgE Recurrent Infection Syndrome, Immune Deficiency
Interventions: Ranitidine, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Duloxetine; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Thoracolumbar Scoliosis
Interventions: Methadone, Normal Saline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fasciitis, Plantar
Interventions: AmnioFix® Injectable, Saline Injection; Other · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Fresno, California • San Francisco, California + 7 more

Conditions: Diabetic Neuropathy
Interventions: Intraneural Facilitation, Sham; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Lateral Epicondylitis
Interventions: rhPDGF-BB Injection, Placebo; Drug
Lead sponsor: BioMimetic Therapeutics; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more

Conditions: Crohn's Disease
Interventions: adalimumab, placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more

Conditions: Wrinkles, Photoaging, Fine Lines
Interventions: Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen; Procedure · Combination Product
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 70
States / cities: Little Rock, Arkansas • Concord, California • Encino, California + 60 more

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Guanfacine extended release (GXR); Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: 2% Lidocaine jelly, Plain aqueous gel; Drug
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Facial Pain, Rhinosinusitis
Interventions: Erenumab Prefilled Syringe, Placebo; Drug · Other
Lead sponsor: David Jang, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Effects of Hallucinogens and Other Drugs on Mood and Performance

Anthrax AV7909 Boost Evaluation Study

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

Antioxidant Replacement Therapy in Patients With Alcohol Abuse

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

Duloxetine for Perimenopausal Depression

A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test

Erenumab for Idiosyncratic Facial Pain